TNFSF10 and glioblastoma: MSCs were engineered with both to deliver TRAIL and to specifically recognize GD2 through a truncated anti-GD2 CAR in order to improve their retention in the targeted GD2 positive tumors like glioblastoma, sarcomas and neuroblastoma [46].